BioSpace News Archive

The global CAR T-cell therapy market size was estimated at USD 2.20 billion in 2022 and it is expected to surpass around USD 6.48 billion by 2032, poised to grow at a CAGR of 11.4% from 2023 to 2032.

Cyclacel Pharmaceuticals, Inc. announced that it will implement a 1-for-15 Reverse Stock Split of its common stock, effective at 5:00 p.m. Eastern Time on Friday, December 15, 2023.

Amgen announced that its Board of Directors declared a $2.25 per share dividend for the first quarter of 2024.

TransMedics Group, Inc. announced that on December 7, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 9,547 shares of its common stock and an aggregate of 6,175 restricted stock units to 11 employees, each as a material inducement for each employee’s entry into employment with TransMedics.

Champions Oncology, Inc., a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced its financial results for its second quarter of fiscal 2024, ended October 31, 2023.

ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms, announces the presentation of non-clinical summary data for the best-in-class selective FLT3 clinical candidate at the 65th ASH Annual Meeting and Exposition in San Diego, CA.

MedX Health Corp. is pleased to announce that it is making an Application to the TSX-V for Acceptance of the proposed amendment to the terms of the currently outstanding Convertible Loan Notes.

HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China.

BioArctic AB’s partner Eisai announced that LEQEMBI will be launched in Japan on December 20, following its scheduled inclusion in the price listing on the Japan National Health Insurance drug price list.

The global cell transfection market is expected to expand at a remarkable CAGR during the forecast period from 2023 to 2032.